Neuronetics (STIM) Competitors $1.03 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends STIM vs. DRIO, PYPD, PAVM, ICAD, KRMD, GUTS, TLSI, SRTS, EDAP, and PDEXShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include DarioHealth (DRIO), PolyPid (PYPD), PAVmed (PAVM), iCAD (ICAD), KORU Medical Systems (KRMD), Fractyl Health (GUTS), TriSalus Life Sciences (TLSI), Sensus Healthcare (SRTS), Edap Tms (EDAP), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry. Neuronetics vs. DarioHealth PolyPid PAVmed iCAD KORU Medical Systems Fractyl Health TriSalus Life Sciences Sensus Healthcare Edap Tms Pro-Dex Neuronetics (NASDAQ:STIM) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Does the media refer more to STIM or DRIO? In the previous week, Neuronetics and Neuronetics both had 2 articles in the media. Neuronetics' average media sentiment score of 0.00 equaled DarioHealth'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DarioHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor STIM or DRIO? DarioHealth received 110 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.45% of users gave Neuronetics an outperform vote while only 67.04% of users gave DarioHealth an outperform vote. CompanyUnderperformOutperformNeuroneticsOutperform Votes12868.45% Underperform Votes5931.55% DarioHealthOutperform Votes23867.04% Underperform Votes11732.96% Do analysts rate STIM or DRIO? Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 353.07%. DarioHealth has a consensus price target of $4.00, suggesting a potential upside of 322.16%. Given Neuronetics' higher probable upside, analysts plainly believe Neuronetics is more favorable than DarioHealth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75DarioHealth 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in STIM or DRIO? 53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 9.8% of Neuronetics shares are owned by insiders. Comparatively, 16.5% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, STIM or DRIO? Neuronetics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Is STIM or DRIO more profitable? Neuronetics has a net margin of -45.06% compared to DarioHealth's net margin of -265.33%. DarioHealth's return on equity of -74.64% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-45.06% -109.00% -31.72% DarioHealth -265.33%-74.64%-43.99% Which has preferable valuation and earnings, STIM or DRIO? Neuronetics has higher revenue and earnings than DarioHealth. Neuronetics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$71.35M0.44-$30.19M-$1.12-0.92DarioHealth$20.35M1.46-$59.43M-$1.18-0.80 SummaryNeuronetics beats DarioHealth on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.22M$4.41B$5.40B$8.53BDividend YieldN/A42.37%5.13%4.14%P/E Ratio-0.9238.74115.5615.18Price / Sales0.4465.071,484.3492.77Price / CashN/A49.1039.6634.07Price / Book0.874.264.665.02Net Income-$30.19M$11.52M$119.06M$225.46M7 Day Performance4.04%1.04%0.80%0.37%1 Month Performance37.33%0.92%5.65%3.57%1 Year Performance-11.21%39.40%36.76%29.44% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics2.5995 of 5 stars$1.03flat$4.67+353.1%-10.4%$31.22M$71.35M-0.92180News CoverageDRIODarioHealth2.1152 of 5 stars$0.97+3.7%$4.00+312.4%-6.2%$29.03M$19.15M-0.82200Upcoming EarningsPYPDPolyPid2.2598 of 5 stars$3.32-4.3%$14.00+321.7%-14.3%$15.93MN/A-0.3380Gap DownHigh Trading VolumePAVMPAVmed4.1617 of 5 stars$1.07+7.0%$21.00+1,862.6%-73.0%$11.14M$2.45M-0.1390Positive NewsGap UpICADiCAD0.461 of 5 stars$1.96+4.8%N/A+37.9%$52.02M$18.80M-17.8267Short Interest ↑KRMDKORU Medical Systems1.3649 of 5 stars$2.53+0.4%$3.33+31.8%+20.5%$115.78M$30.82M-10.1280Short Interest ↑Gap DownGUTSFractyl Health1.6187 of 5 stars$2.37-5.6%$22.00+828.3%N/A$113.59M$120,000.000.00102Gap UpTLSITriSalus Life Sciences3.5166 of 5 stars$4.07-1.0%$12.50+207.1%-8.2%$110.54M$24.74M-1.63106News CoverageGap UpSRTSSensus Healthcare3.2263 of 5 stars$6.37-1.1%$10.00+57.0%+209.9%$104.42M$36.37M15.5440Positive NewsEDAPEdap Tms2.2551 of 5 stars$2.73+8.3%$14.00+412.8%-57.7%$101.28M$65.42M-4.71307Upcoming EarningsPDEXPro-Dex1.6249 of 5 stars$29.07+2.0%$30.00+3.2%+108.7%$96.51M$53.84M46.89140News CoverageGap Up Related Companies and Tools Related Companies DRIO Competitors PYPD Competitors PAVM Competitors ICAD Competitors KRMD Competitors GUTS Competitors TLSI Competitors SRTS Competitors EDAP Competitors PDEX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STIM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
